Sechenov School
Home › Microbiology › Respiratory Syncytial Virus

Respiratory Syncytial Virus

Human respiratory syncytial virus

For medical students2 min readUpdated 2026-10-10

Respiratory syncytial virus (RSV) is an RNA-containing pathogen that predominantly affects the lower respiratory tract. The infection is most dangerous for newborns and infants in their first months of life, in whom it frequently causes severe forms of bronchitis and pneumonia.

FamilyParamyxoviridae, genus Pneumovirus
GenomeSingle-stranded helical negative-sense RNA
Risk groupInfants in the first 6 months of life
Incubation period3 to 5 days

Structure and Antigenic Properties

RSV is a classic member of the genus Pneumovirus. Inside the polymorphic virion, which can be either spherical or filamentous, lies the genetic material — single-stranded helical negative-sense RNA.

Unlike many other paramyxoviruses, this pathogen completely lacks the surface enzymes hemagglutinin and neuraminidase. The outer lipoprotein envelope contains specific structural proteins that play a key role in the infectious process:

Its antigenic structure allows the virus to be divided into two main serogroups: A and B.

Epidemiology and Stability

The only source of infection in nature is an infected human. Transmission occurs via two main routes:

  1. Aerosol (classic droplet mechanism via coughing or sneezing).
  2. Contact-mediated (transmission via contaminated hands, household items, and linens).

Pathogen contagiousness is high, accounting for 3 to 16% of all registered acute respiratory infections (ARIs). The virus circulates actively in the population: by three years of age, 75% of children already have detectable protective virus-neutralizing antibodies (IgA).

Despite high infectivity, the virus is extremely unstable in the external environment. It is rapidly inactivated by standard physical and chemical factors.

Pathogenesis and Clinical Presentation

The portal of entry for the infection is the epithelium of the upper respiratory tract. Following the incubation period, the virus actively replicates in epithelial cells, leading to cell death.

The disease manifests as a typical ARI, but the infection tends to spread rapidly down into the lower respiratory tract, causing tracheobronchitis or pneumonia. The pathological process is aggravated by the formation of immune complexes, which trigger immunopathological reactions that enhance lung tissue damage. Concurrently, a secondary immunodeficiency develops against the background of the infection.

Principles of Microbiological Diagnostics

To isolate the pathogen, nasopharyngeal secretions or lung tissue samples are sent to the laboratory. A strict pre-analytical rule: the test material must never be frozen.

The mainstay of diagnosis is the classic virological method — inoculation of cell cultures (e.g., continuous lines or primary monkey kidney cultures).

Mnemonic

Remember glycoprotein functions by their starting letters: G — Getting attached (adhesion to receptors), F — Forming syncytia (fusion of membranes).

Frequently asked questions

What classic lower respiratory tract disease (besides pneumonia) is a hallmark of RSV infection in infants?

The classic lower respiratory tract disease characteristic of respiratory syncytial infection in infants is acute bronchiolitis. This inflammatory condition predominantly affects the small bronchi and bronchioles in young children (especially during the first year of life). RSV serves as the primary causative agent of this pathology, which frequently manifests as acute viral respiratory illness in this age group. In infants during their first months of life, the virus can also cause severe bronchitis.

What drugs are used for specific passive immunoprophylaxis of RSV infection in premature infants and high-risk groups?

For specific passive immunoprophylaxis of respiratory syncytial infection in high-risk infants, the monoclonal antibody preparation palivizumab is used, which is specific to RSV. The drug is administered intramuscularly during the seasonal peak of incidence. For patients with 5q spinal muscular atrophy, palivizumab is indicated during the first two years of life.

What rapid diagnostic methods are used for the direct detection of RSV antigens in nasopharyngeal swabs?

To directly detect respiratory syncytial virus antigens in nasopharyngeal mucosa swabs, the following rapid diagnostic methods are used:

  • Immunochromatographic assay (ICA) — allows rapid identification of pathogen antigens for the timely initiation of targeted therapy.
  • Direct and indirect fluorescent antibody (DFA/IFA) tests — used to detect viral antigens directly within cells.
  • Enzyme-linked immunosorbent assay (ELISA) — also applied for antigen detection in the test sample.

The optimal timeframe for rapid testing is the first two days from symptom onset.

Why is the virus called 'syncytial'?

The virus received its name due to its characteristic cytopathic effect. In cell culture, it causes the membranes of adjacent infected cells to fuse, forming giant multinucleated structures known as symplasts and syncytia.

Does lasting immunity develop after a past infection?

No, post-infection immunity is short-lived. Repeat episodes of the disease (reinfections) are possible, although they generally run a significantly milder course.

How does the virus attach to cells if it lacks hemagglutinin?

The attachment function to the receptors of sensitive target cells in RSV is carried out by the specific surface glycoprotein G.

Go deeper

More topics in Microbiology

Nontuberculous MycobacteriaClostridium botulinumProteusRelapsing FeversChlamydophila pneumoniae: Pathogen of Respiratory ChlamydiosisPathogenesis and Clinical Features of InfluenzaHepatitis A VirusDNA Oncogenic Viruses: Mechanism of TransformationClinical Presentation of HIV InfectionJapanese Encephalitis VirusTrichophytosis: Types, Pathogens and MorphologyParacoccidioidomycosisMicrobiology →